{"product_id":"prld-vrio-analysis","title":"Prelude Therapeutics Incorporated (PRLD): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Prelude Therapeutics Incorporated (PRLD)'s potential competitive advantage! This VRIO analysis distills whether its core resources are truly Valuable, Rare, Inimitable, and Organized for sustained market leadership - read on to see the verdict.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrelude Therapeutics Incorporated (PRLD) - VRIO Analysis: First Core Capabilities \/ Resources: Proprietary Targeted Protein Degradation (TPD) Platform\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at how Prelude Therapeutics Incorporated's core technology - their Proprietary Targeted Protein Degradation (TPD) Platform - stacks up against competitors. Honestly, in the biotech space, the platform is the asset, and the recent strategic moves show they are putting their chips down on its unique capabilities.\u003c\/p\u003e\n\n\u003cp\u003eThe platform's value proposition is clear: it enables the creation of novel, highly selective small molecule degraders against targets previously considered 'undruggable,' which promises potentially superior efficacy and safety compared to older inhibitor methods. This isn't just theory; they have concrete programs demonstrating this capability.\u003c\/p\u003e\n\n\u003ch3\u003eVRIO Assessment for TPD Platform\u003c\/h3\u003e\n\u003cp\u003eHere’s the quick math on how this core resource scores across the VRIO dimensions:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eDimension\u003c\/td\u003e\n      \u003ctd\u003eAssessment\u003c\/td\u003e\n      \u003ctd\u003eSupporting Evidence\/Implication\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003eYes\u003c\/td\u003e\n      \u003ctd\u003eEnables novel, highly selective small molecule degraders against previously 'undruggable' targets, offering potentially superior efficacy and safety over traditional inhibitors.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003eYes\u003c\/td\u003e\n      \u003ctd\u003eThe specific expertise in developing first-in-class oral degraders (like the \u003cstrong\u003eKAT6A\u003c\/strong\u003e program) and proprietary payloads for next-gen Antibody Drug Conjugates (ADCs) is relatively rare in the market.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003eHigh Cost\/Difficulty\u003c\/td\u003e\n      \u003ctd\u003eHigh, as it relies on deep, tacit knowledge in medicinal chemistry and structural biology built over years, not just off-the-shelf technology. Translating this into multiple distinct programs (JAK2, KAT6A) is hard to copy quickly.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003eStrong\u003c\/td\u003e\n      \u003ctd\u003eThe company is clearly organizing R\u0026amp;D around this platform, evidenced by multiple degrader programs and external validation, like the \u003cstrong\u003e$60 million\u003c\/strong\u003e upfront\/equity deal with Incyte for the JAK2V617F program.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003eSustained Potential\u003c\/td\u003e\n      \u003ctd\u003eSustained, provided they continue to generate novel, patentable payloads and successfully translate them into clinical candidates, such as the \u003cstrong\u003eKAT6A\u003c\/strong\u003e degrader on track for an IND filing in mid-2026.\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eTranslating Platform Strength to Financial Focus\u003c\/h3\u003e\n\u003cp\u003eThe platform’s perceived strength is directly reflected in the recent capital infusion. As of September 30, 2025, Prelude Therapeutics had \u003cstrong\u003e$58.2 million\u003c\/strong\u003e in cash, cash equivalents, restricted cash, and marketable securities. However, the November 2025 Incyte deal added \u003cstrong\u003e$60 million\u003c\/strong\u003e, extending their preliminary cash runway into 2027. This funding is critical as they focus resources, having paused the SMARCA2 program to prioritize the IND-track assets.\u003c\/p\u003e\n\n\u003cp\u003eTheir operational focus is sharp, which supports the Organization component of VRIO. For the third quarter of 2025, Research and Development (R\u0026amp;D) expenses were \u003cstrong\u003e$21.7 million\u003c\/strong\u003e, down from \u003cstrong\u003e$29.5 million\u003c\/strong\u003e year-over-year, reflecting this resource alignment. The platform’s success is their lifeline; TTM revenue as of September 30, 2025, was only \u003cstrong\u003e$10.5 million\u003c\/strong\u003e, showing near-total reliance on partnerships and financing.\u003c\/p\u003e\n\n\u003ch3\u003eKey Pipeline Milestones Tied to TPD\u003c\/h3\u003e\n\u003cp\u003eThe platform’s success is measured by its clinical output. You need to track these near-term inflection points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eKAT6A Degrader:\u003c\/strong\u003e IND filing targeted for mid-2026.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eJAK2V617F Inhibitor:\u003c\/strong\u003e Lead candidate advancing, with an IND filing expected in the first quarter of 2026.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDegrader Payloads:\u003c\/strong\u003e Development of proprietary payloads for next-generation ADCs, including \u003cstrong\u003eSMARCA2\/4\u003c\/strong\u003e and \u003cstrong\u003eCDK9\u003c\/strong\u003e degraders, continues, with an expanded collaboration with AbCellera.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhat this estimate hides is the execution risk; preclinical success doesn't guarantee clinical efficacy, but the platform’s selectivity is what makes the assets rare.\u003c\/p\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrelude Therapeutics Incorporated (PRLD) - VRIO Analysis: Second Core Capabilities \/ Resources: Advanced JAK2V617F Inhibitor Program\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eTargets a primary driver mutation in myeloproliferative neoplasms (MPNs), a well-validated mechanism with a large patient population, such as the 95% of Polycythemia Vera patients harboring the JAK2V617F mutation.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMPN Indication\u003c\/th\u003e\n\u003cth\u003eJAK2V617F Mutation Frequency\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePolycythemia Vera (PV)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e95%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEssential Thrombocythemia (ET)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyelofibrosis (MF)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e55%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe prevalence of this mutation in the general population is estimated around 0.2%.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eWhile JAK2 inhibitors exist, the mutant selective JH2 inhibitor approach, exemplified by PRT12396, aims for differentiation in a crowded field by showing activity superior to ruxolitinib in multiple preclinical models.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eCompetitors are also pursuing this space, but Prelude's lead candidate is advanced, with an Investigational New Drug (IND) filing expected in the \u003cstrong\u003efirst quarter of 2026\u003c\/strong\u003e. The program operates under an exclusive option agreement with Incyte announced in \u003cstrong\u003eNovember 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe program is prioritized, with preclinical data accepted for oral presentation at the \u003cstrong\u003eDecember 2025 ASH meeting\u003c\/strong\u003e, showing active management.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIND filing for the lead candidate is on track for \u003cstrong\u003eQ1 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePrelude reported a net loss of \u003cstrong\u003e$19.7 million\u003c\/strong\u003e for the third quarter ended \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company projects a cash runway extending into \u003cstrong\u003e2027\u003c\/strong\u003e based on preliminary estimates as of \u003cstrong\u003eNovember 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary, but significant near-term value, as successful Phase 1 data could unlock major partnership value.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrelude Therapeutics Incorporated (PRLD) - VRIO Analysis: Third Core Capabilities \/ Resources: Highly Selective Oral KAT6A Degrader Program\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAddresses an emerging, clinically validated target (KAT6A) in solid tumors like \u003cstrong\u003eER+ breast cancer\u003c\/strong\u003e, with the potential for improved tolerability versus non-selective inhibitors. Selectively degrading KAT6A showed potential for lower hematologic toxicity, such as being \u003cstrong\u003einactive\u003c\/strong\u003e in a predictive assay for neutropenia (CFU-GM), unlike \u003cstrong\u003eKAT6A\/B inhibitors\u003c\/strong\u003e which resulted in \u003cstrong\u003e45% Gr3 neutropenia\u003c\/strong\u003e as DLT in a clinical trial. The degraders demonstrated potent activity, with a potency of \u003cstrong\u003e\u0026lt;1 nM DC50\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eClaimed as the \u003cstrong\u003eindustry's first reported KAT6A degrader\u003c\/strong\u003e based on currently published patents and literature. Preclinical data supporting this hypothesis were presented at the \u003cstrong\u003eAACR Annual Meeting 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBeing first-in-class implies strong foundational IP protection around the chemical structure and mechanism. The company is advancing a development candidate and is on track to file an \u003cstrong\u003eIND in mid-2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization is showing disciplined progression toward clinical entry.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePreclinical data presented at \u003cstrong\u003eAACR Annual Meeting 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDevelopment candidate has been selected.\u003c\/li\u003e\n\u003cli\u003eOn track to file an \u003cstrong\u003eIND in mid-2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePhase 1 dose escalation study initiation planned for the \u003cstrong\u003esecond half of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained, if the IP holds and the oral bioavailability proves superior in the clinic.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Timeline\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Indication\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eER+ breast cancer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEmerging, clinically-validated target\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProgram Status\u003c\/td\u003e\n\u003ctd\u003eDevelopment Candidate Selected\u003c\/td\u003e\n\u003ctd\u003eAdvancing toward IND-enabling studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical Data Presentation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAACR Annual Meeting 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSupported hypothesis of differentiation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIND Filing Target\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003emid-2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIndicates expected IP strength and development pace\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotency (Degrader)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026lt;1 nM DC50\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHighly potent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrelude Therapeutics Incorporated (PRLD) - VRIO Analysis: Fourth Core Capabilities \/ Resources: Strategic Financial Position and Runway\n\u003c\/h2\u003e\n\u003cp\u003eThe strategic financial position provides a critical buffer, quantified by the cash on hand and recent non-dilutive\/equity financing, directly impacting operational flexibility.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eProvides the necessary capital buffer to fund operations and critical clinical milestones without immediate dilution pressure. The current financial state supports advancement toward key inflection points such as the expected IND filings in 2026 for the JAK2V617F and KAT6A programs.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eLow; many biotechs have cash, but the recent $60 million infusion from Incyte in November 2025 is a key differentiator. This capital comprised an upfront payment of $35 million and a $25 million equity investment as part of the option agreement for the JAK2V617F inhibitor program.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eLow; this is a financial outcome, not an inherent skill, though securing the agreement for up to $910 million in total payments shows management credibility.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eExcellent; they managed cash flow to project runway into 2027 based on preliminary estimates as of Q3 2025, which could extend into the third quarter of 2028 if Incyte exercises its option.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary; cash runs out, but the current runway buys them time to hit value inflection points, such as the expected IND filing for the JAK2V617F program in the first quarter of 2026.\u003c\/p\u003e\n\u003cp\u003eKey financial figures supporting the strategic position are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Marketable Securities (As Reported)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$58.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Marketable Securities (As Reported)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$52 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOctober 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncyte Upfront Payment + Equity Investment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$60 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNovember 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Payments from Incyte Deal\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$910 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eTotal Potential\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway (Post-Incyte)\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePreliminary Estimate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway (Option Exercised)\u003c\/td\u003e\n\u003ctd\u003ePotentially into \u003cstrong\u003eQ3 2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eContingent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$94.76 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Quarter\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$18.19 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Quarter\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOperational and profitability metrics influencing cash burn rate:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Loss for Q3 2025: \u003cstrong\u003e$19.7 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) Expenses for Q3 2025: \u003cstrong\u003e$21.7 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eGeneral and Administrative (G\u0026amp;A) Expenses for Q3 2025: \u003cstrong\u003e$5.2 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eRevenue for Q3 2025: \u003cstrong\u003e$6.5 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTrailing Twelve Months (TTM) Loss Per Share: \u003cstrong\u003e-$1.47\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrelude Therapeutics Incorporated (PRLD) - VRIO Analysis: Fifth Core Capabilities \/ Resources: Integrated Chemical Biology and Translational Expertise\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows for rapid design, optimization, and testing of novel small molecules against specific genetic drivers, accelerating the path from discovery to IND-enabling studies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e \u003cstrong\u003eModerate\u003c\/strong\u003e; many firms have chemistry, but Prelude integrates structural biology and biomarker strategy effectively, as seen in their SMARCA2 program.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e \u003cstrong\u003eModerate\u003c\/strong\u003e; it's embedded in the team's know-how, which is hard to replicate quickly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e \u003cstrong\u003eStrong\u003c\/strong\u003e; their entire pipeline is built on this integrated approach, moving multiple first\/best-in-class programs forward.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e \u003cstrong\u003eSustained\u003c\/strong\u003e, as long as the core scientific leadership, including CEO Dr. Kris Vaddi, remains in place.\u003c\/p\u003e\n\u003cp\u003eThe integration is evidenced by the advancement of multiple differentiated assets stemming from their platform expertise:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProgram\/Platform\u003c\/th\u003e\n\u003cth\u003eTarget\/Mechanism\u003c\/th\u003e\n\u003cth\u003eStatus\/Key Data Point\u003c\/th\u003e\n\u003cth\u003eQuantifiable Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePRT3789\u003c\/td\u003e\n\u003ctd\u003eSMARCA2 Degrader (IV)\u003c\/td\u003e\n\u003ctd\u003ePhase 1 Monotherapy Dose Escalation Complete\u003c\/td\u003e\n\u003ctd\u003eApproximate \u003cstrong\u003e17%\u003c\/strong\u003e Objective Response Rate (ORR) in Class 1 mutation patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePRT7732\u003c\/td\u003e\n\u003ctd\u003eSMARCA2 Degrader (Oral)\u003c\/td\u003e\n\u003ctd\u003ePhase 1 Enrollment Stage\u003c\/td\u003e\n\u003ctd\u003eIND filing planned for mid-2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrecision ADC Platform\u003c\/td\u003e\n\u003ctd\u003eSMARCA2\/4 Dual Degrader Payloads\u003c\/td\u003e\n\u003ctd\u003ePreclinical Data Presented\u003c\/td\u003e\n\u003ctd\u003eDemonstrated improved tumor regression in prostate cancer models vs. traditional therapies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Pipeline\u003c\/td\u003e\n\u003ctd\u003eDrug Candidates\u003c\/td\u003e\n\u003ctd\u003eTotal Programs\u003c\/td\u003e\n\u003ctd\u003eTotal Funding raised of \u003cstrong\u003e$145M\u003c\/strong\u003e over \u003cstrong\u003e4 rounds\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organizational strength supporting this capability is reflected in the financial and operational execution:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and Development Expenses for the full year 2024 were \u003cstrong\u003e$118 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and marketable securities as of December 31, 2024, totaled \u003cstrong\u003e$133.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe cash runway was estimated to extend into the second quarter of 2026 based on December 31, 2024 figures, subsequently estimated to extend into \u003cstrong\u003e2027\u003c\/strong\u003e based on Q3 2025 figures.\u003c\/li\u003e\n\u003cli\u003eThird-quarter 2025 Research and Development expenses declined to \u003cstrong\u003e$21.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnnual revenue as of December 31, 2024, was \u003cstrong\u003e$7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company reported a net loss of \u003cstrong\u003e$127.2 million\u003c\/strong\u003e for 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrelude Therapeutics Incorporated (PRLD) - VRIO Analysis: Sixth Core Capabilities \/ Resources: Degrader Antibody Conjugate (DAC) Technology\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Extends the reach of their small molecule degraders (like SMARCA2\/4) to potentially address a larger patient population via targeted delivery, combining two powerful modalities.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e \u003cstrong\u003eHigh\u003c\/strong\u003e; developing proprietary payloads specifically optimized for DACs is an advanced, specialized area of drug development.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e \u003cstrong\u003eHigh\u003c\/strong\u003e; this requires mastering both TPD payload design and ADC conjugation chemistry.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e \u003cstrong\u003eDeveloping\u003c\/strong\u003e; they have a partnership with AbCellera and presented preclinical data on their SMARCA2\/4 degrader payloads for ADCs in \u003cstrong\u003eOctober 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e \u003cstrong\u003eTemporary, but high potential\u003c\/strong\u003e; it’s a platform-level resource that could yield significant future value if successfully commercialized.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDAC Program\/Payload\u003c\/th\u003e\n\u003cth\u003eKey Milestone\/Data Point\u003c\/th\u003e\n\u003cth\u003eDate\/Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSMARCA2\/4 DACs\u003c\/td\u003e\n\u003ctd\u003eFirst preclinical data presented demonstrating potential for significantly better \u003cem\u003ein vivo\u003c\/em\u003e efficacy and tolerability vs. traditional cytotoxic ADCs\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eOctober 2025\u003c\/strong\u003e (36th EORTC-NCI-AACR Symposium)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSMARCA2\/4 DACs\u003c\/td\u003e\n\u003ctd\u003eAnticipate nominating the first development candidate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emCALR-targeted DACs\u003c\/td\u003e\n\u003ctd\u003eFirst preclinical data presented\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eJune 2025\u003c\/strong\u003e (European Hematology Association 2025 Congress)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSMARCA2\/4 \u0026amp; CDK9 Payloads\u003c\/td\u003e\n\u003ctd\u003ePayloads developed optimized for efficacy, tolerability and developability\u003c\/td\u003e\n\u003ctd\u003eOngoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbCellera Collaboration\u003c\/td\u003e\n\u003ctd\u003eScope amended and expanded; received additional license payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOctober 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe technology platform is supported by the following financial and pipeline context:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents, restricted cash and marketable securities as of \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e were \u003cstrong\u003e$\\text{77.3 million}$\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnticipated initial first-in-human data update for a program by the \u003cstrong\u003esecond half of 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eA KAT6A DAC is expected to enter clinical trials in \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Company anticipates its existing cash, cash equivalents, restricted cash and marketable securities will fund operations into \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrelude Therapeutics Incorporated (PRLD) - VRIO Analysis: Seventh Core Capabilities \/ Resources: Management Team's Oncology Drug Development Experience\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Reduces execution risk in navigating complex clinical trials, regulatory hurdles, and strategic decision-making in the oncology space.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many companies have experienced leaders, but Prelude's team has specific experience with precision oncology and targeted therapies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; institutional knowledge and established relationships within the industry are not easily copied.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good; the team is actively making tough calls, like pausing the IV SMARCA2 degrader (PRT3789) to focus resources on the oral PRT7732.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as long as the key leaders, like Dr. Vaddi, continue to drive strategy.\u003c\/p\u003e\n\n\u003cp\u003eThe depth of experience within the management team, particularly in oncology drug development and execution, supports the \u003cstrong\u003eValue\u003c\/strong\u003e proposition.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eExecutive Role\u003c\/th\u003e\n\u003cth\u003eRelevant Experience Metric\u003c\/th\u003e\n\u003cth\u003eKey Achievement\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEO, Kris Vaddi, Ph.D.\u003c\/td\u003e\n\u003ctd\u003eFounded Prelude in \u003cstrong\u003e2016\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eInitiated and championed JAK research programs at Incyte leading to approval of Jakafi® (ruxolitinib) and Olumiant® (baricitinib).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePresident \u0026amp; CMO, Jane Huang, M.D.\u003c\/td\u003e\n\u003ctd\u003eOversaw approval of zanubrutinib in \u003cstrong\u003e3\u003c\/strong\u003e diseases spanning more than \u003cstrong\u003e45\u003c\/strong\u003e countries (at BeiGene).\u003c\/td\u003e\n\u003ctd\u003eOversaw global clinical development of acalabrutinib (at Acerta Pharma).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCBO, Sean Brusky\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e20 years\u003c\/strong\u003e of biopharma business development experience; over \u003cstrong\u003e15 years\u003c\/strong\u003e at Genentech\/Roche.\u003c\/td\u003e\n\u003ctd\u003eFocus on delivering precision oncology innovations to patients.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSVP, Clinical Pharmacology, Sri Sahasranaman\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e20 years\u003c\/strong\u003e of drug development experience, including oncology.\u003c\/td\u003e\n\u003ctd\u003eProvided clinical pharmacology leadership for \u003cstrong\u003efour NDA\/BLA\u003c\/strong\u003e and multiple sNDA\/sBLA filings.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCFO\/CLO, Bryant D. Lim\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e20 years\u003c\/strong\u003e of experience in pharma and biotech.\u003c\/td\u003e\n\u003ctd\u003ePreviously served as Vice President of Legal at Incyte Corporation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCCO, Andrew Combs, Ph.D.\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e27 years\u003c\/strong\u003e of experience as a medicinal chemist.\u003c\/td\u003e\n\u003ctd\u003eHeld roles at Incyte Corporation, most recently as Vice President of Discovery Chemistry.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe team's track record in advancing novel assets demonstrates organizational capability:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSince inception in \u003cstrong\u003e2016\u003c\/strong\u003e, the company has received clearance for \u003cstrong\u003efour INDs\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eThree\u003c\/strong\u003e of those programs have been advanced into clinical development.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe strategic resource allocation decision highlights the organizational aspect:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company decided to pause further development of PRT3789 (IV SMARCA2 degrader) to focus solely on PRT7732 (oral SMARCA2 degrader) as the go-forward strategy for the SMARCA2 Program (as of August 2025).\u003c\/li\u003e\n\u003cli\u003eAs of December 31, 2024, the company reported $133.6 million in cash, cash equivalents, and marketable securities, funding operations into the second quarter of 2026.\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) Expenses for the year ended December 31, 2024, were $118.0 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrelude Therapeutics Incorporated (PRLD) - VRIO Analysis: Eighth Core Capabilities \/ Resources: Strategic Partnership with AbCellera\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Provides access to a leading antibody discovery engine to rapidly generate novel Antibody Drug Conjugates (ADCs) using Prelude’s proprietary payloads.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate; partnerships are common, but this one is focused on integrating two distinct, cutting-edge technologies (TPD + Antibody Discovery).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Low; the specific terms and history of collaboration are unique to this pairing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Good; the partnership is active, evidenced by a license payment received in \u003cstrong\u003eOctober 2025\u003c\/strong\u003e, showing mutual commitment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary; the advantage is in the current execution of the joint programs, which needs to yield clinical success.\u003c\/p\u003e\n\n\u003cp\u003eThe strategic collaboration scope and progress are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eDetail\u003c\/th\u003e\n\u003cth\u003eValue\/Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollaboration Type\u003c\/td\u003e\n\u003ctd\u003eJointly discover, develop, and commercialize novel oncology medicines\u003c\/td\u003e\n\u003ctd\u003eMulti-program\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Programs\u003c\/td\u003e\n\u003ctd\u003eUp to this number of precision ADC targets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFive\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst Program Focus\u003c\/td\u003e\n\u003ctd\u003eADCs utilizing Prelude's SMARCA2 selective degraders\u003c\/td\u003e\n\u003ctd\u003ePrecision ADC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst Development Candidate Nomination\u003c\/td\u003e\n\u003ctd\u003eAnticipated timeframe for nomination\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecent Financial Event\u003c\/td\u003e\n\u003ctd\u003eLicense payment received from expanded agreement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOctober 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey operational divisions within the partnership:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAbCellera leads \u003cstrong\u003emanufacturing\u003c\/strong\u003e activities.\u003c\/li\u003e\n\u003cli\u003ePrelude leads \u003cstrong\u003eclinical development\u003c\/strong\u003e and global commercialization.\u003c\/li\u003e\n\u003cli\u003eAbCellera holds an option to co-promote resulting commercial products in the \u003cstrong\u003eUnited States\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePreclinical data demonstrated potential for significantly better \u003cem\u003ein vivo\u003c\/em\u003e efficacy and tolerability compared to traditional cytotoxic ADCs when tested head-to-head in xenograft models.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePrelude Therapeutics Incorporated (PRLD) - VRIO Analysis: Ninth Core Capabilities \/ Resources: Focus on Biomarker-Driven Patient Selection\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Increases the probability of clinical success by testing therapies in genetically defined patient subsets with high unmet need, like SMARCA4-deficient cancers. For PRT3789 monotherapy in advanced NSCLC or esophageal patients with Class 1 SMARCA4 mutations (as of November 30, 2024 data cutoff), 5 RECIST confirmed partial responses were observed out of 32 evaluable patients.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; it's the standard for precision medicine, but Prelude is applying it to novel targets like SMARCA2 and JAK2V617F. The JAK2V617F inhibitor program is subject to an exclusive option agreement with Incyte announced in November 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; requires robust translational science capabilities to identify and validate the necessary biomarkers. The company presented preclinical data from its Precision ADC platform in October 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; their entire pipeline is framed around these genetically defined targets, showing organizational alignment. The company anticipates its existing cash, cash equivalents, restricted cash and marketable securities will fund operations into 2027 following the Incyte receipt.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as long as the underlying science continues to validate these specific genetic dependencies in cancer.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinance: Draft 13-Week Cash Flow View Incorporating November Incyte Receipt\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCash, cash equivalents, restricted cash and marketable securities as of September 30, 2025, totaled \u003cstrong\u003e$58.2 million\u003c\/strong\u003e. The Incyte transaction provided an immediate capital infusion of \u003cstrong\u003e$60 million\u003c\/strong\u003e in November 2025. The full year 2024 net loss was \u003cstrong\u003e$127.2 million\u003c\/strong\u003e. Research and Development (R\u0026amp;D) Expenses for the third quarter of 2024 were \u003cstrong\u003e$29.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCash Flow Item\u003c\/th\u003e\n\u003cth\u003eWeek 1 (Post-Receipt)\u003c\/th\u003e\n\u003cth\u003eWeek 2\u003c\/th\u003e\n\u003cth\u003eWeek 3\u003c\/th\u003e\n\u003cth\u003eWeek 4\u003c\/th\u003e\n\u003cth\u003eWeek 5\u003c\/th\u003e\n\u003cth\u003eWeek 6\u003c\/th\u003e\n\u003cth\u003eWeek 7\u003c\/th\u003e\n\u003cth\u003eWeek 8\u003c\/th\u003e\n\u003cth\u003eWeek 9\u003c\/th\u003e\n\u003cth\u003eWeek 10\u003c\/th\u003e\n\u003cth\u003eWeek 11\u003c\/th\u003e\n\u003cth\u003eWeek 12\u003c\/th\u003e\n\u003cth\u003eWeek 13\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeginning Cash Balance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$118.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$115.93 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$113.66 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$111.39 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$109.12 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$106.85 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$104.58 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$102.31 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$100.04 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$97.77 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$95.50 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$93.23 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$90.96 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncyte Receipt (Upfront + Equity)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$60.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Weekly Operating Cash Outflow (Proxy based on Q3'24 R\u0026amp;D)\u003c\/td\u003e\n\u003ctd\u003e$2.27 million\u003c\/td\u003e\n\u003ctd\u003e$2.27 million\u003c\/td\u003e\n\u003ctd\u003e$2.27 million\u003c\/td\u003e\n\u003ctd\u003e$2.27 million\u003c\/td\u003e\n\u003ctd\u003e$2.27 million\u003c\/td\u003e\n\u003ctd\u003e$2.27 million\u003c\/td\u003e\n\u003ctd\u003e$2.27 million\u003c\/td\u003e\n\u003ctd\u003e$2.27 million\u003c\/td\u003e\n\u003ctd\u003e$2.27 million\u003c\/td\u003e\n\u003ctd\u003e$2.27 million\u003c\/td\u003e\n\u003ctd\u003e$2.27 million\u003c\/td\u003e\n\u003ctd\u003e$2.27 million\u003c\/td\u003e\n\u003ctd\u003e$2.27 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnding Cash Balance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$115.93 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$113.66 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$111.39 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$109.12 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$106.85 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$104.58 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$102.31 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$100.04 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$97.77 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$95.50 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$93.23 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$90.96 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$88.69 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eNote: Beginning Cash Balance for Week 1 is calculated as \u003cstrong\u003e$58.2 million\u003c\/strong\u003e (Sep 30, 2025 cash) + \u003cstrong\u003e$60.0 million\u003c\/strong\u003e (Incyte receipt). Weekly Outflow is a hypothetical constant derived from Q3 2024 R\u0026amp;D expense ($29.5 million \/ 13 weeks $\\approx$ $2.27 million\/week).\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIncyte equity investment involved the purchase of \u003cstrong\u003e6.25 million\u003c\/strong\u003e shares at \u003cstrong\u003e$4.00\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eThe JAK2V617F program is subject to an exclusive option agreement with Incyte.\u003c\/li\u003e\n\u003cli\u003eThe company anticipates cash runway into \u003cstrong\u003e2027\u003c\/strong\u003e post-transaction.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516234817685,"sku":"prld-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/prld-vrio-analysis.png?v=1740207391","url":"https:\/\/dcf-model.com\/products\/prld-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}